Sai Life Sciences Limited
IPO Details
Subscription
Lot Distribution
Reservation
Company Fin.
₹71(12.93%)
Premium (ELP)
Sai Life Sciences Limited's successfully completed its Initial Public Offering and commenced trading on Dec 18, 2024 at the NSE, BSE exchange. The company raised 5,54,21,123 Shares through this public offering, comprising 1,73,04,189 Shares in fresh capital and ₹2092.62 Cr through the Offer for Sale mechanism.
The IPO was priced within the band of ₹522 to ₹549, with minimum application lots of 27 shares. The offering attracted significant investor interest during its subscription period from Dec 11, 2024 to Dec 13, 2024.
Share allotment was finalized on Dec 16, 2024, distributing equity to successful applicants. The stock's subsequent listing marked a significant milestone in the company's corporate history, providing public market liquidity to shareholders.
Investors can bid starting from the minimum lot size specified for this IPO, and only in multiples of that lot size. The table below shows the minimum and maximum investment for retail investors and HNIs in terms of lots, quantity, and amount.
Sai Life Sciences Limited, incorporated in January 1999, specializes in researching, developing, and manufacturing small-molecule new chemical entities, serving over 280 innovator pharmaceutical companies in FY 2024, including more than 230 clients as of September 2024. Collaborating with 18 of the top 25 global pharmaceutical firms, the company provides services across the US, UK, Europe, and Japan, offering CMC/CDMO capabilities, integrated discovery through CRO services, and support in biology, chemistry, and pharmacokinetics. Supported by a workforce of 3,135 employees, including 2,353 scientific staff with 302 Ph.D.s and 1,475 master’s degrees, Sai Life Sciences drives innovation with a globally positioned business development team of 16 professionals.
Note : "Calculations for ‘Shares Offered’ and ‘Total Amount’ are based on the highest price in the issue price band."
- Integrated Platform: Offers end-to-end services from drug discovery to manufacturing.
- Diverse Portfolio: Capable of managing molecules across early-stage and commercial phases.
- Advanced Capabilities: Leverages cutting-edge technologies in biology, chemistry, and DMPK.
- Customer Dependency: A significant portion of revenue comes from biotechnology and pharmaceutical clients, making the company vulnerable to industry-specific challenges, such as delays or failures in drug development and manufacturing.
- Compliance Risks: Failure to meet customer standards during audits or inspections could damage reputation and potentially result in termination of contracts.
- Market Uncertainties: Changes in customer demand, regulatory landscape, or industry trends may adversely affect business performance and growth prospects.
- Kanumuri Ranga Raju
- Krishnam Raju Kanumuri
- Kanumuri Mytrey
- Sai Quest Syn Private Limited
- Sunflower Partners
- Lily Partners
- Marigold Partners
- Tulip Partners
Sai Life Sciences Limited
Kfin Technologies Limited